Selvita stock gains 2.25 percent as subsidiaries plan merger

Published on 10/06/2026 at 12:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Selvita stock trades at PLN 22.70 on October 6, 2026, with PLN 416.6 million in market value. H1 sales fell 14 percent to PLN 158.1 million.

Selvita, PLSLVCR00029, Illustration mit AI erstellt.

Selvita (ISIN PLSLVCR00029) was trading at PLN 22.70 on the Warsaw Stock Exchange on October 6, 2026, up 2.25 percent from PLN 22.20. The latest corporate development is a plan to merge two wholly owned subsidiaries, while the company's half-year figures show a tougher operating backdrop.

Subsidiaries prepare for integration

Selvita Services agreed to absorb PozLab under a plan dated September 30, 2026. According to GPW Alert, the transaction is intended to simplify the group structure and create operating, cost and commercial synergies.

The planned combination does not change the consolidated financial statements because both subsidiaries are already included in Selvita's group accounts, GPW Alert reported on October 1, 2026. The strategic value is therefore organizational rather than an immediate revenue increase.

Half-year sales fall 14 percent

Selvita's sales revenue reached PLN 158.1 million in the six months ended June 30, 2026, down from PLN 183.8 million a year earlier. According to Quartr, adjusted EBITDA fell 23 percent year over year to PLN 23.9 million, while the net loss widened to PLN 8.5 million from PLN 5.6 million.

The second quarter showed the same pressure. Investing.com reported on September 18, 2026, that quarterly sales were PLN 82.14 million, compared with PLN 93.48 million a year earlier, and adjusted EBITDA was PLN 12.56 million versus PLN 16.02 million.

Backlog shifts toward development

The order mix provides a counterweight to the weaker group result. Backlog stood at PLN 305.7 million on September 15, 2026, down 8.5 percent year over year, but Drug Development backlog rose 23 percent while Drug Discovery backlog fell 23 percent, according to Quartr.

That split matters because the stronger development division partly offsets pressure in discovery services. Quartr also reported PLN 16.6 million of cash at June 30, 2026, while operating cash flow for the first half was PLN 2.2 million.

Analyst target stays above market

MarketScreener lists an Outperform consensus from 6 analysts, with an average price target of PLN 35.85 and a published spread of 59.33 percent above a PLN 22.50 last close. Against the October 6 price of PLN 22.70, the average target lies 57.9 percent above the stock.

Selvita stock stays near yearly low

Selvita stock was trading at PLN 22.70 on October 6, 2026, with a 52-week range of PLN 20.20 to PLN 49.40 and market capitalization of PLN 416.6 million. The quote sits 12.4 percent above the yearly low, keeping execution in Drug Development and recovery in Drug Discovery central to the valuation debate.